What is Invion?
Invion is dedicated to transforming cancer therapy through its pioneering work in Photodynamic Therapy (PDT). The company holds exclusive rights to the Photosoft technology across key regions in the Asia Pacific and North America, positioning it at the forefront of developing innovative treatments for various forms of cancer. Its research and clinical trials are supported by an R&D services agreement with the technology licensor, RMW Cho Group Limited. Invion is publicly traded on the ASX under the ticker IVX.
How much funding has Invion raised?
Invion has raised a total of $2M across 1 funding round:
Share Placement
$2M
Share Placement (2025): $2M, investors not publicly disclosed
What's next for Invion?
With this major strategic investment, Invion is well-positioned to further its clinical development and commercialization efforts for its Photosoft technology. The company's focus on advancing PDT for cancer treatment, coupled with its established licensing agreements, suggests a trajectory aimed at significant market penetration. Future strategic moves will likely involve expanding clinical trial reach, securing further regulatory approvals, and potentially forging new partnerships to broaden the application of its therapies. The enterprise-level backing indicates confidence in Invion's long-term growth potential and its capacity to deliver impactful solutions in oncology.
See full Invion company page
